On March 7, 2018Clovis Oncology, Inc. (Nasdaq: CLVS) reported that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Thursday, March 15, 2018 at 8:00 AM Eastern Time (Press release, Clovis Oncology, MAR 7, 2018, View Source;p=RssLanding&cat=news&id=2336864 [SID1234524501]). The conference will be held at the Loews Miami Beach Hotel in Miami.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

On March 7, 2018 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that it will release its financial results for fourth quarter and fiscal year 2017 after the close of trading on Wednesday, March 14, 2018 (Press release, Quanterix, MAR 7, 2018, View Source [SID1234524521]). Company management will host a conference call at 4:30 p.m. EDT to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Individuals interested in listening to the conference call may do so by dialing (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following password: 5079049. A live webcast will be accessible on the Investors section of Quanterix’ website: View Source The webcast will be available on the Company’s website for one year following completion of the call.

On March 7, 2018 Novavax, Inc. (Nasdaq:NVAX) reported it will provide a corporate update and report its fourth quarter and full year 2017 financial and operating results following the close of U.S. financial markets on Wednesday, March 14, 2018 (Press release, Novavax, MAR 7, 2018, http://ir.novavax.com/news-releases/news-release-details/novavax-host-conference-call-and-webcast-provide-corporate [SID1234524619]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call and webcast details are as follows:

Date: March 14, 2018

Time: 5:00 p.m. U.S. Eastern Time (ET)

Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)

Passcode: 6472939

Webcast: www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates: Starting at 8:00 p.m. ET, March 14, 2018 until

9:00 p.m. ET March 21, 2018

Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)

Passcode: 6472939

Webcast: www.novavax.com, "Investors"/ "Events", until June 14

Regulus has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Regulus, 2018, MAR 7, 2018, View Source [SID1234524548]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

on March 7, 2018 Cerus Corporation (NASDAQ: CERS) reported that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 38th Annual Health Care Conference at 8:00 am ET on Tuesday, March 13, 2018 (Press release, Cerus, MAR 7, 2018, View Source [SID1234524479]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at View Source A replay will be available for approximately two weeks following the completion of the event.